|09/07/17||GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO|
|PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled ... |
|08/30/17||Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker|
|PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210.
The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy expert... |
|08/03/17||Adaptimmune Reports Second Quarter 2017 Financial Results|
|– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –
– Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different tumor indications –
– On track for initial data from our wholly-owned assets in 2017 and 2018 –
– NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting (ASCO) c... |
|07/31/17||Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017|
|PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017.
The Company will not be hosting a live teleconference this quarter. The press release will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com.
About Adapti... |